Running Behind "POPO"-Impact of Predictors of Poor Outcome for Treatment Stratification in Pediatric Crohn's Disease

被引:1
作者
de Laffolie, Jan [1 ]
Zimmer, Klaus-Peter [1 ]
Sohrabi, Keywan [2 ]
Hauer, Almuthe Christina [3 ]
机构
[1] Univ Giessen, Dept Gen Pediat & Neonatol, Pediat Gastroenterol, Giessen, Germany
[2] Tech Univ Giessen, Dept Med IT, Giessen, Germany
[3] Med Univ Graz, Dept Pediat & Adolescent Med, Graz, Austria
关键词
pediatric Crohn's disease; outcome parameters; predictors of a poor prognosis; patient registry; big data; INFLAMMATORY-BOWEL-DISEASE; GROWTH-RETARDATION; INFLIXIMAB; CHILDREN; MANAGEMENT; PHENOTYPE; SURGERY; THERAPY; ONSET; RISK;
D O I
10.3389/fmed.2021.644003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Aims: Intensifying therapy for Paediatric Crohn's Disease (CD) by early use of immunomodulators and biologics has been proposed for cases in which predictors of poor outcome (POPO) were present. We investigated therapy stratifying potential comparing POPO-positive and -negative CD patients from CEDATA-GPGE (R), a German-Austrian Registry for Paediatric Inflammatory Bowel disease.Methods: CD patients (1-18 years) registered in CEDATA-GPGE (R) (2004-2018) within 3 months of diagnosis and at least two follow-up visits were included. Disease course and treatments over time were analysed regarding positivity of POPO criteria and test statistical properties.Results: 709/1084 patients included had at least one POPO criterion (65.4%): 177 patients (16.3%) had persistent disease (POPO2), 581 (53.6%) extensive disease (POPO3), 21 (1.9%) severe growth retardation POPO4, 47 (4.3%) stricturing/penetrating disease (POPO6) and 122 (11.3%) perianal disease (POPO7). Patients with persistent disease differed significantly in lack of sustained remission >1 year (Odd Ratio (OR) 1.49 [1.07-2.07], p = 0.02), patients with initial growth failure in growth failure at end of observation (OR 51.16 [19.89-131.62], p < 0.0001), patients with stricturing and penetrating disease as well as perianal disease in need for surgery (OR 17.76 [9.39-33.58], p < 0.001; OR 2.56 [1.58-4.15], p < 0.001, respectively). Positive Predictive Value for lack of sustained remission was >60% for patients with initial growth failure, persistent or stricturing/penetrating disease.Conclusion: Predictors of poor outcome with complicated courses of disease were common in CEDATA-GPGE (R). An early intensified approach for paediatric CD patients with POPO-positivity (POPO2-4, 6-7) should be considered, because they have an increased risk to fare poorly.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Long-Term Follow-up and Predictors of Complicated Disease Behavior in Pediatric Crohn's Disease Patients
    Kori, Michal
    Avidan, Maya
    Topf-Olivestone, Chani
    JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2022, 74 (04) : 471 - 475
  • [2] Efficacy of early treatment with infliximab in pediatric Crohn's disease
    Lee, Jong Seung
    Lee, Jee Hyun
    Lee, Ji Hyuk
    Lee, Hye Jin
    Kim, Mi Jin
    Lee, Hae Jeong
    Choe, Yon Ho
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (14) : 1776 - 1781
  • [3] Impact of Abdominal Visceral Adipose Tissue on Disease Outcome in Pediatric Crohn's Disease
    Uko, Victor
    Vortia, Eugene
    Achkar, Jean-Paul
    Karakas, Pinar
    Fiocchi, Claudio
    Worley, Sarah
    Kay, Marsha H.
    INFLAMMATORY BOWEL DISEASES, 2014, 20 (12) : 2286 - 2291
  • [4] Repeated exclusive enteral nutrition in the treatment of paediatric Crohn's disease: predictors of efficacy and outcome
    Frivolt, K.
    Schwerd, T.
    Werkstetter, K. J.
    Schwarzer, A.
    Schatz, S. B.
    Bufler, P.
    Koletzko, S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (12) : 1398 - 1407
  • [5] The safety of treatment options for pediatric Crohn's disease
    Grossi, Victoria
    Hyams, Jeffrey S.
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (10) : 1383 - 1390
  • [6] Nutritional therapy for the treatment of pediatric Crohn's disease
    Otley, Anthony R.
    Russell, Richard K.
    Day, Andew S.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2010, 6 (04) : 667 - 676
  • [7] Evaluating the impact of infliximab use on surgical outcomes in pediatric Crohn's disease
    Abbas, Paulette I.
    Peterson, Michelle L.
    Fallon, Sara C.
    Lopez, Monica E.
    Wesson, David E.
    Walsh, Seema M.
    Kellermayer, Richard
    Rodriguez, J. Ruben
    JOURNAL OF PEDIATRIC SURGERY, 2016, 51 (05) : 786 - 789
  • [8] Long-term Outcome of Treatment with Infliximab in Pediatric-onset Crohn's Disease: A Population-Based Study
    Crombe, Valerie
    Salleron, Julia
    Savoye, Guillaume
    Dupas, Jean-Louis
    Vernier-Massouille, Gwenola
    Lerebours, Eric
    Cortot, Antoine
    Merle, Veronique
    Vasseur, Francis
    Turck, Dominique
    Gower-Rousseau, Corinne
    Lemann, Marc
    Colombel, Jean-Frederic
    Duhamel, Alain
    INFLAMMATORY BOWEL DISEASES, 2011, 17 (10) : 2144 - 2152
  • [9] Zoledronic acid for the treatment of osteopenia in pediatric Crohn's disease
    Sbrocchi, Anne Marie
    Forget, Sylviane
    Laforte, Diane
    Azouz, E. Michel
    Rodd, Celia
    PEDIATRICS INTERNATIONAL, 2010, 52 (05) : 754 - 761
  • [10] Histology at diagnostic gastroscopy predicts outcome after intestinal resection in pediatric Crohn's disease
    Tan, Zien Vanessa
    Kosana, Kiranmai
    Savarino, Jeffrey
    Croft, Nicholas
    Naik, Sandhia
    Kaplan, Jess
    Giles, Edward
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 (12) : 2074 - 2079